Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Audrey Abella, 05 Oct 2020
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.

PRoFeSs score reliably predicts poor outcomes in severe community-acquired pneumonia

11 Aug 2019

The PRoFeSs score―which includes the Charlson score, as well as levels of day 3 lactate, day 1 and day 3 procalcitonin, day 3 D-dimer, and day 1 brain-type natriuretic peptide (BNP)―can identify severe community-acquired pneumonia (SCAP) patients at high risk of poor outcomes 5 days after ICU admission, a recent study has found.

Researchers conducted a single-centre, prospective cohort study including 107 ICU patients (mean age, 62.0±15.7 years; 60.7 percent male) diagnosed with SCAP. The study’s primary outcome included death and the lack of ≥2-point improvements in scores in the Sequential Organ Failure Assessment within 5 days of treatment.

Six variables emerged as significantly predictive of the primary outcome. For instance, Charlson score (adjusted odds ratio [OR], 1.330, 95 percent CI, 1.059–1.669; p=0.021) and day 3 concentrations of D-dimer (adjusted OR, 2.185, 1.352–3.530; p=0.001) were strongly and positively correlated with the likelihood of the primary outcome.

The same was true for day 3 concentrations of procalcitonin (adjusted OR, 1.635, 0.993–4.692; p=0.016) and lactate (adjusted OR, 1.954, 1.093–3.498; p=0.03).

In comparison, day 1 levels of BNP (adjusted OR, 0.950, 0.901–1.001; p=0.047) and procalcitonin (adjusted OR, 0.572, 0.355–0.922; p=0.003) were significantly but inversely correlated with the primary outcome.

Consolidating all factors into one predictive model produced the PRoFeSs score, which had an area under the receiver operating characteristic curve of 0.81 (0.72–0.89). At a cutoff of 3 points, sensitivity and specificity are both maximized, yielding values of 79 percent and 71 percent, respectively.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Audrey Abella, 05 Oct 2020
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.